Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardioxyl Pharmaceuticals

Latest From Cardioxyl Pharmaceuticals

Appointments: Shire, Bicycle Therapeutics, Gilead Sciences, Astellas, Alzheon, Alnylam and Amplyx

2017 begins with three Novartis executives finding new roles and high-level appointments made by Shire, Bicycle Therapeutics, Gilead Science and Amplyx Pharmaceuticals.

Appointments BioPharmaceutical

Bristol-Myers' Mike Burgess Talks R&D Challenges, Portfolio Developments In 2017

Dr. Mike Burgess, the head of several disease R&D areas at Bristol-Myers Squibb, talks to Scrip on the side lines of the recent One Nucleus Genesis conference in London, UK, about the importance of a diverse portfolio, balancing R&D budgets and his industry-wide predictions for 2017.

Commercial Companies

2015 Exits: Biotech’s Big Year

Fewer companies went public in 2015 than during the peak year of 2014, but on average 2015’s US IPO crop raised more money and at better valuations. And thanks to a jump in private biotech acquisition volume and valuations, investors enjoyed a tremendous year for biotech exits.

BioPharmaceutical Business Strategies

Biopharma Quarterly Dealmaking Statistics, Q4 2015

Biopharma financing for Q4 totaled $13.1 billion, a 35% increase over Q3, and again was dominated by follow-on public offerings. M&A reached a record $201 billion, topped by Pfizer's $160 billion buy of Allergan. Sanofi's $4.2 billion diabetes collaboration with Hanmi led the alliances.

BioPharmaceutical Deals
See All

Company Information